Biosimilar Master Class

In our first lesson, Dr. Robert Rifkin, McKesson’s Medical Director of Biosimilars, and Tim Ho, Clinical Specialist, provide a foundational understanding of biosimilars. Their conversation covers the differences between generics and biosimilars, the FDA’s position and guidelines, and the science behind developing biosimilar therapies.

Watch the video to learn the foundation and science behind biosimilars

In our second lesson, Derek Burns, Clinical Specialist, discusses new biosimilar expansion across specialties and what your practice can do to begin preparing. He also covers clinical considerations of non-oncology practices and what to keep in mind for developing a biosimilar action plan specific to your practice.

Watch the video on how to to prepare a biosimilar action plan specific to your practice

In our final lesson, Jason Ballash, Director of Multisource Programs, and John Griffith, Director of Clinical Services, take a look at the path ahead for the biosimilars. They provide an insightful overview of the biosimilar pipeline, highlighting notable launches on the horizon with a clinical perspective on trends in the market.

Watch the video to understand the biosimilar pipeline and market trends from a clinical perspective

If your specialty practice is preparing to adopt biosimilars, McKesson can help. We clear the path by creating a roadmap for success. Our advisors and resources can help you navigate every step of the biosimilar journey, from patient education to developing training programs. McKesson also supports specialty practices like yours with communicating the facts clearly, implementing efficient workflows and driving operational excellence so you can focus on what matters most - caring for your patients.